AstraZeneca paid $100 million upfront to secure ex‑China rights to Jacobio Pharma’s clinical‑stage pan‑KRAS inhibitor JAB‑23E73, expanding its oncology footprint, company releases show. Separately, AstraZeneca reported a phase 3 failure for ceralasertib in lung cancer, with the study missing its primary endpoint. The two announcements together underscore a portfolio reshuffle: the Jacobio deal pushes AstraZeneca deeper into KRAS‑targeted small molecules, while the synthetic‑lethal ceralasertib setback signals a pause for that mechanism in certain indications. The juxtaposition reflects large pharma’s simultaneous dealmaking and clinical risk exposure across oncology programs.